Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease

[1]  A. Evans,et al.  Interaction of CSF α‐synuclein and amyloid beta in cognition and cortical atrophy , 2021, Alzheimer's & dementia.

[2]  A. Toga,et al.  Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease , 2020, Annals of neurology.

[3]  Luis Carrasco,et al.  Polygenic risk and pleiotropy in neurodegenerative diseases , 2020, Neurobiology of Disease.

[4]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[5]  Jong Hun Kim,et al.  Effect of polygenic load on striatal dopaminergic deterioration in Parkinson disease , 2019, Neurology.

[6]  A. Singleton,et al.  Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[7]  Alan C. Evans,et al.  Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction , 2019, Neurology.

[8]  Nick C Fox,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[9]  J. Trojanowski,et al.  Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders , 2018, Annals of neurology.

[10]  W. M. van der Flier,et al.  α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies , 2018, Movement disorders : official journal of the Movement Disorder Society.

[11]  D. Berg,et al.  Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[12]  J. Trojanowski,et al.  CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders , 2018, Neurology.

[13]  B. Ritz,et al.  Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease , 2018, JAMA neurology.

[14]  B. Gavett,et al.  The Differential Effects of Alzheimer's Disease and Lewy Body Pathology on Cognitive Performance: a Meta-analysis , 2016, Neuropsychology Review.

[15]  T. Montine,et al.  Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis , 2017, The Lancet Neurology.

[16]  J. Schott,et al.  Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study , 2017, The Lancet Neurology.

[17]  K. Blennow,et al.  Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid , 2016, Alzheimer's & Dementia.

[18]  M. Toft,et al.  A cumulative genetic risk score predicts progression in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[19]  Arthur W. Toga,et al.  CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study , 2016, Acta Neuropathologica.

[20]  Michelle K. Lupton,et al.  Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases , 2016, Neurobiology of Aging.

[21]  M. Nalls,et al.  Polygenic risk of Parkinson disease is correlated with disease age at onset , 2015, Annals of neurology.

[22]  A. Schapira,et al.  Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. , 2015, JAMA neurology.

[23]  T. Montine,et al.  APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. , 2014, JAMA neurology.

[24]  T. Hortobágyi,et al.  Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias , 2014, Brain pathology.

[25]  Carson C Chow,et al.  Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.

[26]  K. Cain,et al.  Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. , 2014, The American journal of pathology.

[27]  Arthur W Toga,et al.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. , 2013, JAMA neurology.

[28]  J. Trojanowski,et al.  CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease , 2013, Acta Neuropathologica.

[29]  D. Na,et al.  Effects of education on the progression of early- versus late-stage mild cognitive impairment , 2012, International Psychogeriatrics.

[30]  John L. Robinson,et al.  Neuropathologic substrates of Parkinson disease dementia , 2012, Annals of neurology.

[31]  D. Berg,et al.  GBA-associated PD presents with nonmotor characteristics , 2011, Neurology.

[32]  Constantinos Kallis,et al.  Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? , 2011, Brain : a journal of neurology.

[33]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[34]  John P A Ioannidis,et al.  Meta-analysis in genome-wide association studies. , 2009, Pharmacogenomics.

[35]  K. Jellinger,et al.  Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease , 2008, Acta Neuropathologica.

[36]  F. Schmidt.  Meta-Analysis , 2008 .

[37]  K. Jellinger,et al.  Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease , 2002, Journal of Neural Transmission.

[38]  Dr. Ron Short.  Diagnosis? , 1987, The Lancet.

[39]  M. F. Parry,et al.  A Retrospective Analysis , 1990 .